Navigation Links
FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
Date:12/10/2009

CAMBRIDGE, Mass., Dec. 10 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) approved Cequent's first IND (investigational new drug) application yesterday. This action enables Cequent to initiate the first-ever trial of an orally administered RNA interference drug in humans: CEQ508 - the company's lead drug candidate based on its proprietary tkRNAi technology. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

The IND application acceptance is the second procedural hurdle that the young company has cleared in order to begin human clinical trials of CEQ508 in the FAP (familial adenomatous polyposis) patient population. The company noted that the 14 reviewing members of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH) voted unanimously to endorse the proposed clinical protocol after conducting an in-depth review and public discussion of the proposed CEQ508 program on September 9, 2009.*

"We submitted our IND application to the FDA on November 9, 2009. Having our first IND application accepted in the 30-day period is an extraordinary accomplishment for any company, particularly so for Cequent, given that we are working on an entirely new class of drugs," said Cequent Chief Executive Officer Peter Parker. "It speaks volumes to the quality of the submission, which comprised more than 4,000 pages. I'm so proud of our scientific team, who, in a short time, were successful in turning an intriguing RNAi research concept into a viable drug candidate ready to be tested in humans."

The FDA approved Cequent's proposed clinical protocol for the Phase I clinical trial, including
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
2. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
3. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
4. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
5. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
6. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
7. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
11. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... Dec. 23, 2014  Advanced Medical Isotope Corporation ... primarily in the development of brachytherapy devices and ... announced that it has filed a de ... Administration ("FDA") for marketing clearance for its patented ... the U.S. Food, Drug and Cosmetic Act (the ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... BETHLEHEM, Pa., April 26, 2011 In collaboration ... for Anticancer Drug Research (CESAR) announced today that ... paclitaxel therapeutic drug management (TDM) with subsequent pharmacokinetic-guided ... non-small cell lung cancer (NSCLC).  The study will ...
... International Limited (NYSE: MR ), a leading developer, ... it will report its financial results for the first quarter ... May 9, 2011. Mindray,s management will hold an earnings conference ... Time (8:00 PM on May 10, 2011 Beijing/Hong Kong Time). ...
Cached Medicine Technology:Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 2Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 3Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 4Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 5Mindray to Report First Quarter 2011 Financial Results on May 9, 2011 2
(Date:12/26/2014)... Los Angeles, CA (PRWEB) December 26, 2014 ... buyer power score of 3.1 out of 5. This ... from a low level of product specialization, low switching ... buyer power is reduced by the low availability of ... in the world price of steel and aluminum, key ...
(Date:12/26/2014)... The Biofeedback Federation of Europe annual ... in Rome, Italy and is hosted by the Salesian ... on a wide variety of topics such as ADHD, ... training in athletes. The scientific program will feature the ... monitoring allows clients to see what is going on ...
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/26/2014)... 26, 2014 Parker & Sons, ... best in heating, cooling and plumbing contractor services ... emergency services in 2014 with regard to air-conditioning ... Arizona is known for its incredibly hot summers. ... the intricacies and details of a wide variety ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3
... UK and US working together explained that they have ... rare, progressive childhood //disorders caused by an abnormal build ... about the discovery of the PLA2G6 gene, whose mutated ... they said that this could also shed light on ...
... have conceived a new way of freezing human eggs which will ... //, to be able to have children. , ,Women’s eggs ... thawed, in contrast to sperms which can be easily frozen and ... by the Japanese researchers which hold promise over the present technique ...
... Director of Fertile Hope has given birth to a baby girl ... // event for Beck who was diagnosed with tongue cancer at ... permanent infertility. ,Facing a void of resources concerning ... educate herself. Upon learning her of her risk of infertility, she ...
... by her biological parents a ... left to drown in an ... But the little infant survived ... a critical heart surgery. ...
... during childbirth to ease the pain during labor. But such ... The National Patient Safety Agency (NPSA) in response has issued ... show that about 200 errors have been committed due a ... to be administered at the base of the spine, but ...
... cancer can talk to doctor through their beloved ones, especially ... ,The head of the Prostate Cancer Foundation, Leslie ... are daughters, wives and partners whom can realize their role ... prostrate cancer. ,More than 27,000 men were ...
Cached Medicine News:Health News:Rare Nerve Disease Causing Gene Identified 2Health News:Cancer Survivor Gives Birth To Baby Girl 2
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Woodlyn Lensmeter is designed to be used in either a prescription laboratory setting or professional office. Its titable position angle offers personal comfort. The easily operated marking device pro...
Nidek Fundus Camera NM-200D's compact, lightweight body with user-friendly color touch screen display provides more options to treat more patients, and is more comfortable to use....
Medicine Products: